171 filings
Page 6 of 9
8-K
6v53lsy in
11 Aug 11
Trius Therapeutics Reports 2011 Second Quarter Financial Results
12:00am
8-K
6vio8oukd
5 Aug 11
Trius Therapeutics Obtains Special Protocol Assessment with Fda for Second Phase 3 Study of Torezolid Phosphate
12:00am
424B3
wvny h7plpnll
5 Aug 11
Prospectus supplement
12:00am
8-K
i8usrg2j7wsl55vusak5
27 Jul 11
Trius Therapeutics and Bayer Form Strategic Collaboration to
12:00am
424B3
nzwwlpk2vy2u 69o8x
27 Jul 11
Prospectus supplement
12:00am
424B3
mcvuv3d36 vi
6 Jul 11
Prospectus supplement
12:00am
EFFECT
pof8a2pn
6 Jul 11
Notice of effectiveness
12:00am
D
hf0h78o1smgfjh166
7 Jun 11
$44.29M in equity / options / securities to be acquired, sold $30.16M, 25 investors
12:00am
8-K
pti4nap
3 Jun 11
Submission of Matters to a Vote of Security Holders
12:00am
8-K
t9ekwi0vxbgv7
25 May 11
Trius Therapeutics Announces Pricing of $30 Million Financing
12:00am
ARS
1hkoj0w8dh40nypwyt7m
16 May 11
Annual report to shareholders
12:00am
8-K
bjtt23
5 May 11
Trius Therapeutics Reports 2011 First Quarter Financial Results
12:00am
DEF 14A
deg0z0
20 Apr 11
Definitive proxy
12:00am
10-K
x1f0fn87 esl4
25 Mar 11
Annual report
12:00am
S-8
xwlr4
25 Mar 11
Registration of securities for employees
12:00am
8-K
ywiyr 2nty1226y8
23 Mar 11
Trius Therapeutics Reports Fourth Quarter and Full Year 2010 Financial Results
12:00am
8-K
zm5s6 g1rgxpi0r0
28 Feb 11
Trius Announces Positive Results from Phase 1 Lung Study of
12:00am